Drug class
Poly(ADP-ribose) Polymerase Inhibitors clinical trials
A class of medicines: the studies that test any of its 39 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the poly(adp-ribose) polymerase inhibitors studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Abiraterone Acetate/Niraparib
- 2
- PARP 1/2 Inhibitor TQB3823
- 2
- Atamparib
- 2
- PARP1 Inhibitor SNV1521
- 2
- PARP1 Inhibitor HS-10502
- 2
- E-7016
- 2
- PARP1 Inhibitor ACE-86225106
- 1
- PARP 1/2 Inhibitor RP12146
- 1
- Basroparib
- 1
- ABT-767
- 1
- AZD2461
- 1
- Palacaparib
- 1
- PARP1 Inhibitor DSB2455
- 1
- PARP1 Inhibitor IMP1734
- 1
- PARP/Microtubule Polymerization Inhibitor AMXI-5001
- 1
- PARP7 Inhibitor BY101921
- 1
- Prodrug PARP Inhibitor TSL-1502
- 1
- Simmiparib
- 1
Studies by the year they started
981 studies that test it; most in 2019 (111); 1 more planned to start later
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 14 |
| 2008 | 20 |
| 2009 | 13 |
| 2010 | 34 |
| 2011 | 27 |
| 2012 | 25 |
| 2013 | 19 |
| 2014 | 32 |
| 2015 | 28 |
| 2016 | 58 |
| 2017 | 60 |
| 2018 | 77 |
| 2019 | 111 |
| 2020 | 98 |
| 2021 | 85 |
| 2022 | 84 |
| 2023 | 68 |
| 2024 | 62 |
| 2025 | 38 |
| 2026 | 23 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 353 · Other 630
National Cancer Institute (NCI) (96) · AstraZeneca (73) · Jiangsu HengRui Medicine Co., Ltd. (29) · M.D. Anderson Cancer Center (23) · Pfizer (21) · Merck Sharp & Dohme LLC (20) · Tesaro, Inc. (19) · pharmaand GmbH (18)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 983
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationRecruitingPhase 2National Cancer Institute (NCI)NCT04858334Written as Olaparib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Olaparib
- Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT05873192Written as Talazoparib
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingPhase 3Merck Sharp & Dohme LLCNCT03486873Written as Olaparib
- Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)RecruitingPhase 1/2National Cancer Institute (NCI)NCT04086485Written as Olaparib
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)RecruitingPhase 3AstraZenecaNCT07711002Written as Saruparib
- A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationRecruitingPhase 3AstraZenecaNCT06952803Written as Saruparib
- Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate CancerRecruitingPhase 1/2AstraZenecaNCT07590934Written as Palacaparib (AZD9574)
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesRecruitingPhase 1/2AstraZenecaNCT05123482Written as AZD8205 and AZD5305 (saruparib)
- Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based ChemotherapyRecruitingPhase 2Abramson Cancer Center at Penn MedicineNCT06747845Written as Niraparib
- A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)RecruitingPhase 1Merck Sharp & Dohme LLCNCT07199465Written as Letermovir
- A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric PatientsRecruitingPhase 3Children's Oncology GroupNCT05711667Written as Letermovir
- Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate CancerRecruitingPhase 2Fundacion OncosurNCT06582628Written as Enzalutamide capsule and Talazoparib capsule
- Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerRecruitingPhase 2Bai-Rong XiaNCT05652283Written as Pamiparib
- Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart TransplantRecruitingPhase 2/3Columbia UniversityNCT07079735Written as Letermovir
- Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell TumorsNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07850973Written as Olaparib
- Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + BevacizumabRecruitingPhase 2Peking University Cancer Hospital & InstituteNCT06141265Written as Niraparib
- Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid TumoursRecruitingPhase 1/2AstraZenecaNCT07446855Written as Saruparib
- Letermovir for R+ StudyNot yet recruitingPhase 4University of Wisconsin, MadisonNCT07706166Written as Letermovir
- WIRE - Novel Treatments in Renal Cell CancerRecruitingPhase 2CCTU- Cancer ThemeNCT03741426Written as Olaparib
See all 983 studies that test one of the poly(adp-ribose) polymerase inhibitors →
Codes
What other systems call Poly(ADP-ribose) Polymerase Inhibitors · ClinicalTrials.gg INT006499
- MeSH (NLM) D000067856Poly(ADP-ribose) Polymerase InhibitorsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000067856 | Poly(ADP-ribose) Polymerase Inhibitors | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.